

Freedom of Information Request

Ref: 21-313

11 June 2021

By Email

Dear Sir/Madam

Thank you for your request for information under the Freedom of Information Act 2000. The Trust's response is as follows:

- We can confirm that we hold some the information you are requesting

Q1. In the past 3 months, how many Urothelial cancer patients were treated with the following:

- Atezolizumab: = 4
- Carboplatin with Gemcitabine: = 8
- Carboplatin single or in any other combination: = 0
- Cisplatin with Gemcitabine: = 9
- Cisplatin single or in any other combination: = 0
- Nivolumab: = 0
- Pembrolizumab: = 1
- Any other regimen including Paclitaxel: = 0
- Any other chemotherapy regimen: = 3
- Other active systemic anti-cancer therapy: Avelumab- = 7
- Palliative care only: Our palliative care team have previously advised they are unable to supply this information on similar FOIs due to the vast number of ways patient can be referred to palliative care services, some of which bypass UHBW entirely.

Q2. Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?

Yes: Atlantis (8 patients) and Thor (3 patients)

Q3. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:

- Afatinib:= 2
- Alectinib: = 14
- Atezolizumab monotherapy: = 3
- Atezolizumab + Bevacizumab + Carboplatin + Paclitaxel: = 0

- Bevacizumab:= 0
- Brigatinib: = 2
- Ceritinib: = 0
- Crizotinib: = 0
- Dacomitinib: = 0
- Dabrafenib with Trametinib: = 1
- Docetaxel: = 4
- Durvalumab: = 5
- Erlotinib: = 2
- Gefitinib: = 0
- Gemcitabine: = 12
- Nintedanib with Docetaxel:= 2
- Nivolumab: = 2
- Osimertinib:= 14
- Paclitaxel: = 1
- Pembrolizumab monotherapy: = 49
- Pembrolizumab chemo in combination: = 25
- Pemetrexed with Carboplatin: = 17
- Pemetrexed with Cisplatin: = 0
- Vinorelbine and cisplatin/carboplatin: 1= 3
- Any other active systemic anti-cancer therapy: = 21
- Palliative care only: We do not hold this information

Q4. Does your trust participate in any ongoing clinical trials for the treatment of non-small cell lung cancer (NSCLC)? If so, can you please provide the name of each trial along with the number of patients taking part?

Yes: Saron (5 patients), Matrix (11 patients), SMP (145 patients), Canopy (6 patients), Keynote 867 (2 patients), Halt (0 patients)

This concludes our response. We trust that you find this helpful, but please do not hesitate to contact us directly if we can be of any further assistance.

If, after that, you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of receipt of the response to your original letter and should be addressed to:

Director of Corporate Governance
 University Hospitals Bristol and Weston NHS Foundation Trust
 Trust Headquarters
 Marlborough Street
 Bristol
 BS1 3NU

Please remember to quote the reference number above in any future communications.

If you are not content with the outcome of the internal review, you have the right to apply directly to the Information Commissioner for a decision. The Information Commissioner can be contacted at: Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire, SK9 5AF

Publication

Please note that this letter and the information included/attached will be published on our website as part of the Trust's Freedom of Information Publication Log. This is because information disclosed in accordance with the Freedom of Information Act is disclosed to the public, not just to the individual making the request. We will remove any personal information (such as your name, email and so on) from any information we make public to protect your personal information.

To view the Freedom of Information Act in full please click [here](#).

Yours sincerely

Freedom of Information Team
University Hospitals Bristol and Weston NHS Foundation Trust